These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 11359828)

  • 1. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions.
    Godkin AJ; Smith KJ; Willis A; Tejada-Simon MV; Zhang J; Elliott T; Hill AV
    J Immunol; 2001 Jun; 166(11):6720-7. PubMed ID: 11359828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of human T-cell receptors specific for an immunodominant myelin basic protein peptide: positioning of T-cell receptors on HLA-DR2/peptide complexes.
    Wucherpfennig KW; Hafler DA; Strominger JL
    Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8896-900. PubMed ID: 7568039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones.
    Wucherpfennig KW; Sette A; Southwood S; Oseroff C; Matsui M; Strominger JL; Hafler DA
    J Exp Med; 1994 Jan; 179(1):279-90. PubMed ID: 7505801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex.
    Krogsgaard M; Wucherpfennig KW; Cannella B; Hansen BE; Svejgaard A; Pyrdol J; Ditzel H; Raine C; Engberg J; Fugger L
    J Exp Med; 2000 Apr; 191(8):1395-412. PubMed ID: 10770805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity-determining region 2 peptides from disease-associated T cell receptor BV genes.
    Bourdette DN; Chou YK; Whitham RH; Buckner J; Kwon HJ; Nepom GT; Buenafe A; Cooper SA; Allegretta M; Hashim GA; Offner H; Vandenbark AA
    J Immunol; 1998 Jul; 161(2):1034-44. PubMed ID: 9670985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anergy induction by dimeric TCR ligands.
    Appel H; Seth NP; Gauthier L; Wucherpfennig KW
    J Immunol; 2001 Apr; 166(8):5279-85. PubMed ID: 11290814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells.
    Vergelli M; Kalbus M; Rojo SC; Hemmer B; Kalbacher H; Tranquill L; Beck H; McFarland HF; De Mars R; Long EO; Martin R
    J Neuroimmunol; 1997 Aug; 77(2):195-203. PubMed ID: 9258250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage.
    Carson RT; Vignali KM; Woodland DL; Vignali DA
    Immunity; 1997 Sep; 7(3):387-99. PubMed ID: 9324359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins.
    Li Y; Li H; Martin R; Mariuzza RA
    J Mol Biol; 2000 Nov; 304(2):177-88. PubMed ID: 11080454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pH dependent binding of high and low affinity myelin basic protein peptides to purified HLA-DR2.
    Mukku PV; Passmore D; Phan D; Nag B
    Mol Immunol; 1995 Jun; 32(8):555-64. PubMed ID: 7541890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein.
    Gauthier L; Smith KJ; Pyrdol J; Kalandadze A; Strominger JL; Wiley DC; Wucherpfennig KW
    Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11828-33. PubMed ID: 9751750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cysteinylation of MHC class II ligands: peptide endocytosis and reduction within APC influences T cell recognition.
    Haque MA; Hawes JW; Blum JS
    J Immunol; 2001 Apr; 166(7):4543-51. PubMed ID: 11254711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.
    Fridkis-Hareli M; Santambrogio L; Stern JN; Fugger L; Brosnan C; Strominger JL
    J Clin Invest; 2002 Jun; 109(12):1635-43. PubMed ID: 12070311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell epitope mapping of the Smith antigen reveals that highly conserved Smith antigen motifs are the dominant target of T cell immunity in systemic lupus erythematosus.
    Talken BL; Schäfermeyer KR; Bailey CW; Lee DR; Hoffman RW
    J Immunol; 2001 Jul; 167(1):562-8. PubMed ID: 11418695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses.
    Fridkis-Hareli M; Stern JN; Fugger L; Strominger JL
    Hum Immunol; 2001 Aug; 62(8):753-63. PubMed ID: 11476898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mass tag-assisted identification of naturally processed HLA class II-presented meningococcal peptides recognized by CD4+ T lymphocytes.
    Meiring HD; Kuipers B; van Gaans-van den Brink JA; Poelen MC; Timmermans H; Baart G; Brugghe H; van Schie J; Boog CJ; de Jong AP; van Els CA
    J Immunol; 2005 May; 174(9):5636-43. PubMed ID: 15843563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of complete eluted peptide sequence data from HLA-DR and -DQ molecules to predict T cell epitopes, and the influence of the nonbinding terminal regions of ligands in epitope selection.
    Godkin AJ; Davenport MP; Willis A; Jewell DP; Hill AV
    J Immunol; 1998 Jul; 161(2):850-8. PubMed ID: 9670963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues.
    Arnold PY; La Gruta NL; Miller T; Vignali KM; Adams PS; Woodland DL; Vignali DA
    J Immunol; 2002 Jul; 169(2):739-49. PubMed ID: 12097376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunodominance does not result from peptide competition for MHC class II presentation.
    Lo-Man R; Langeveld JP; Martineau P; Hofnung M; Meloen RH; Leclerc C
    J Immunol; 1998 Feb; 160(4):1759-66. PubMed ID: 9469434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refolding and reconstitution of functionally active complexes of human leukocyte antigen DR2 and myelin basic protein peptide from recombinant alpha and beta polypeptide chains.
    Arimilli S; Cardoso C; Mukku P; Baichwal V; Nag B
    J Biol Chem; 1995 Jan; 270(2):971-7. PubMed ID: 7529765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.